Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 552 of 5804
-
Cheaper keytruda? new biosimilar SB27 tested in lung cancer
Disease control OngoingThe goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients. The main question it aims to answer is: • How effective the study drug is Participants will receive either investigat…
Phase: PHASE3 • Sponsor: Samsung Bioepis Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Experimental CAR T-Cell therapy takes on metastatic prostate cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New cocktail aims to boost immune attack on ovarian cancer
Disease control Recruiting nowThis phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumo…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New liquid biopsy could spot hidden brain lymphoma
Diagnosis OngoingPrevention and treatment of CNS relapse remains a great unmet clinical need in the management of aggressive B-NHL. Hence, investigating novel diagnostic tests is of paramount importance to improve risk-stratification of lymphoma patients at diagnosis, as is the evaluation of nove…
Phase: NA • Sponsor: Swiss Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
Can immune therapy IVIG calm long COVID's autonomic storm?
Disease control OngoingThis study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, mu…
Phase: PHASE2 • Sponsor: Kanecia Obie Zimmerman • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo aims to shrink advanced cervical cancer
Disease control OngoingThis research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.
Phase: PHASE2 • Sponsor: Meghan Shea • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New immunotherapy cocktail targets Hard-to-Treat cancers
Disease control OngoingObjective response rate (ORR) was evaluated to evaluate the efficacy of SHR-8068 combined with adebrelimab and platinum-containing chemotherapy in first-line treatment of advanced gastric and esophageal cancer.
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 13:05 UTC
-
New nasal spray aims to curb relentless hunger in rare genetic disorder
Disease control ENROLLING_BY_INVITATIONTo evaluate long-term safety and tolerability of carbetocin nasal spray (3.2 mg TID) in subjects with PWS
Phase: PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New immunotherapy combo aims to stop merkel cell cancer return
Disease control Recruiting nowThe goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival
Phase: PHASE2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug combo aims to slow cervical cancer growth
Disease control Recruiting nowThe main purpose of this study is to gather information about an investigational drug combination, Lenvatinib in combination with pembrolizumab, that may help to treat cervical cancers. In this study, we are looking to see whether the combination of lenvatinib and pembrolizumab h…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New Gene-Modified immune cells take on tough lymphoma
Disease control Recruiting nowThe goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed/refractory B-lymphoma. The main questions it aims to answer are: Maximum tolerated dose (MTD) Response rates Participants will be treated with the investigational…
Phase: PHASE1, PHASE2 • Sponsor: Instituto de Investigación Biomédica de Salamanca • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Leukemia patients who failed stopping meds may get another shot at drug-free remission
Disease control Recruiting nowTo evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI
Phase: PHASE2 • Sponsor: Korean Society of Hematology • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug cocktail aims to tackle tough esophageal cancer
Disease control Recruiting nowThe goal of this single-arm study is to explore the efficacy and safety of Adebrelimab in combination with Apatinib and Tegafur for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma that has failed first-line standard treatment with PD-1 inhibitor…
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Ancient herbs face off against metformin in diabetes trial
Disease control OngoingThe goal of this clinical trial to learn the clinical efficacy and safety of standardized polyherbal capsule weighing around 500 mg, containing Syzygium cumini, Momordica charantia, Wrightia tinctoria, and Gymnema sylvestre in equal proportions for controlling Diabetic hyperglyce…
Phase: PHASE3 • Sponsor: Hamdard University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill could tame tough psoriasis
Disease control OngoingThe purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New cocktail of drugs shows promise for Tough-to-Treat bile duct cancer
Disease control OngoingThis is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC). The study will include a safety run-in involving 6 study participants. The goal of the safety run-in is to screen for…
Phase: PHASE2 • Sponsor: Nataliya Uboha • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug aims to keep myeloma in check after CAR-T
Disease control Recruiting nowThis research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a peptide shield kidneys during bypass surgery? new trial aims to find out
Disease control Recruiting nowTo evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria: 1. Increase in baseline (pre-surgery) serum creatinine (SCr) by ≥26.5 μmol/L (≥0.3 mg/dL) within 7 days; OR …
Phase: PHASE2 • Sponsor: Arch Biopartners Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can lung cancer patients skip brain radiation? new trial explores alectinib alone first.
Disease control Recruiting nowThis study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in…
Phase: PHASE1, PHASE2 • Sponsor: Joshua Palmer • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Immune reset: CAR-T therapy takes on lupus
Disease control TerminatedThis is an open, Phase I, investigator-initiated study (IIT) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with moderate or severe active SLE. This study will explore the safety of escalating doses of RD06-04 by pre…
Phase: NA • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC